Bariatrics Clinical Trial - Celgene RPC01-3202
Bariatrics
Status:
Open (Study open and enrolling)ClinicalTrials.gov:
NCT03440385CONDITION(S): Crohn Disease - TRIAL: Celgene RPC01-3202 - This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease.